Frankfurt
11.11.26 | 08:03
0,068 Euro
-3,26 % -0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,061 | 0,089 | 11.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | GenSight Biologics S.A.: GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders | 504 | Business Wire | NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
Regulatory News:
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
| GENSIGHT BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 08.10. | GenSight Biologics S.A.: Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa | 712 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 08.10. | GenSight Biologics S.A.: GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders | 719 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics ("GenSight" or the "Company") (Euronext:... ► Artikel lesen | |
| 08.10. | GenSight Biologics S.A.: GenSight Biologics Reports Cash Position as of September 30, 2026 | 534 | Business Wire | €8.2 million in gross cash collections from paid early access programs since the start of treatments in March 2026, including €1.7 million during the third quarter
Paid early access programs... ► Artikel lesen | |
| 30.09. | GenSight Biologics S.A.: GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates | 760 | Business Wire | €6.5 million collected from paid early access programs; after recognition of rebates and a €4.3 million non-cash change in accounting estimate, reported IFRS revenue amounted to €(1.2) million.... ► Artikel lesen | |
| 08.09. | GenSight Biologics Provides September 2026 Business Updates | 603 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 08.07. | GenSight Biologics S.A.: GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates | 4.676 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 20.05. | GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026 | 546 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 18.05. | GenSight Biologics S.A.: GenSight Biologics to Hold its Combined General Meeting on May 19, 2026 | 583 | Business Wire | Combined General Meeting on May 19, 2026
Key operational developments in 2025 and 2026
Regulatory News:
GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME... ► Artikel lesen | |
| 11.05. | GenSight Biologics S.A.: GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments | 508 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 28.04. | GenSight Biologics S.A.: GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026 | 757 | Business Wire | Procedures for obtaining preparatory documents for the General Meeting are described below.
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma... ► Artikel lesen | |
| 15.04. | GenSight Biologics Announces the Filing of its 2025 Universal Registration Document | 549 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 07.04. | GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026 | 644 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 03.04. | GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates | 963 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 27.03. | GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025 | 577 | Business Wire | 2025 was a turning point with key regulatory milestones providing a solid foundation for 2026.
Cash runway is projected to extend through December 2026.
Preparation of the Phase... ► Artikel lesen | |
| 20.03. | The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ | 519 | Business Wire | The first group of patients in the GS010 AAC program were treated at the 15-20 National Hospital in Paris on March 19.
The REVISE dose-ranging study is proceeding according to the planned... ► Artikel lesen | |
| 18.03. | GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising | 715 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
| 09.03. | GenSight Biologics Provides Updates about GS010/LUMEVOQ Early Access Programs and the Ongoing REVISE Study | 747 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| 18.02. | GenSight Biologics S.A.: GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments | 549 | Business Wire | Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing... ► Artikel lesen | |
| 10.02. | GenSight Biologics S.A.: The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ REVISE Study | 663 | Business Wire | First of 14 planned patients for the dose-ranging study approved by the ANSM in December 2025
Clinical study marks continuing partnership between the 15-20 Hospital and GenSight Biologics... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,70 | +0,77 % | 16,6 Milliarden Euro bei BioNTech, 15 neue Therapeuten bei Emyria - woran die Psychedelika-Medizin wirklich hängt | ||
| EVOTEC | 3,116 | -0,06 % | Kurs-Drama bei Palantir! Evotec mit Aufwärtsdrang! Kaufgelegenheit bei Lahontan Gold nach der Konsolidierung! | Die Märkte drehen derzeit teilweise komplett durch. Chipaktien korrigieren prozentual zweistellig. Investoren befürchten, dass die KI-Blase platzt oder das Wachstum nicht mehr in dem Maße weitergeht... ► Artikel lesen | |
| BB BIOTECH | 59,50 | +2,76 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,395 | +0,35 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| MODERNA | 224,20 | -0,27 % | Moderna zwischen Durchbruch und Milliardenrisiko | Moderna erlebt einen bemerkenswerten Wandel an der Börse. Noch vor wenigen Monaten dominierte die Sorge um schrumpfende Corona-Umsätze und hohe Forschungskosten. Inzwischen rückt eine ganz andere Perspektive... ► Artikel lesen | |
| VALNEVA | 2,655 | +2,04 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| AMGEN | 416,60 | -0,01 % | Biotech-Boom: Eli Lilly wächst rasant, Amgen legt nach - und Mesoblast liefert Zelltherapie-Umsätze | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 9,150 | +0,22 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| STRYKER | 288,50 | -0,65 % | Stryker: 179-Millionen-Verkauf - was Anleger wissen müssen | ||
| BIOGEN | 225,45 | -0,60 % | Biogen Inc.: ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure | Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP... ► Artikel lesen | |
| BIOFRONTERA | 3,010 | +0,67 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,140 | +0,47 % | Biotech-Nebenwert im Vergleich: Formycon, Heidelberg Pharma und Medios - 30,0 % Abstand zum höchsten Kursziel | ||
| ILLUMINA | 197,82 | +2,77 % | Illumina Inc. Bottom Line Rises In Q3 | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) announced a profit for its third quarter that Increases, from last yearThe company's bottom line came in at $220 million, or $1.43 per share. This... ► Artikel lesen |
GENSIGHT BIOLOGICS SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,068 Euro und damit -3,26 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENSIGHT BIOLOGICS SA finden Sie auf Wallstreet Online.